Vertex Pharmaceuticals (NASDAQ:VRTX) Rating Increased to Hold at Canaccord Genuity Group
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by stock analysts at Canaccord Genuity Group from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, MarketBeat Ratings reports. The firm currently has a $424.00 target price on the pharmaceutical company’s stock, up from their previous target price of […]
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by stock analysts at Canaccord Genuity Group from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, MarketBeat Ratings reports. The firm currently has a $424.00 target price on the pharmaceutical company’s stock, up from their previous target price of […]
